november AG
november AG: good start into 2004
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG: good start into 2004
Erlangen (Germany), 11 May 2004. In the first quarter of 2004, november AG (ISIN
DE0006762909) has successfully intensified its marketing activities and
achieved a favorable increase of group revenues for the first quarter by 20
percent to EUR 1.142 million (previous year’s period: TEUR 954). At the same
time and reflecting the increased maturity and market readiness of its products,
november achieved to significantly reduce the research and development expenses
by 16 percent to a total of TEUR 737 (previous year’s period: TEUR 882).
At the end of the first quarter, group total liquidity amounted to EUR 11.407
million (previous year: EUR 13.089 million) thus securing the company’s
perspectives. In December 2003, a successful capital increase had led to a gross
inflow of funds of EUR 3.35 million. These additional funds will be
predominantly used for enforcing and accelerating november’s marketing
activities.
First quarter’s consolidated operating result (EBIT) of EUR -1.273 million
remained almost unchanged compared to previous year’s figure (EUR -1.275
million). The consolidated net result including financial and tax result as well
as minority interests was improved by 4 percent to TEUR -797 in comparison to
previous year’s period (TEUR -828). The accumulated deficit per 03/31/2004 was
hence increased by the consolidated net result to TEUR -24,993 (12/31/2003: TEUR
-24,196). The undiluted net earnings per share (EPS according to DVFA/SG) were
improved by 8 percent to EUR -0.11 (previous year’s first quarter: EUR -0.12).
On average, 61 employees (recalculated to full-time terms; not including
employees in minority participations) worked within the november Group
throughout the reporting period from 1 January 2004 to 31 March 2004 (previous
year’s period: 64 employees).
end of ad-hoc-announcement (c)DGAP 11.05.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
Since the spinning-off of the former business divisions “product security /
brand protection” (identif Technologies) and “diagnosis” (directif Diagnostic
Solutions) to wholly-owned subsidiaries effective as of 31 December 2003, four
companies belong to the november Group: november AG, identif GmbH, directif
GmbH, and PEQLAB Biotechnologie GmbH, a molecular biology laboratory supplier in
which november AG holds the majority participation.
identif GmbH has developed and is marketing forgery-proof bio- and nanotech
codes for packaging for pharmaceutical companies and other industries, as well
as novel machine-readable security markings for chip cards, banknotes and
documents. Uniquely, these markings can be authenticated and verified anywhere
within seconds either fully automatically or by using a hand-held mobile
scanner. In March 2004, Bristol-Myers Squibb (Germany) decided to label all its
anti-HIV drugs with identif GmbH’s DNA codes. This is a landmark marketing
success for identif.
Together with Siemens Medical Solutions directif GmbH develops the world’s first
fully automated system for near-patient nucleic acid testing. In a highly
effective manner, pathogens and genetic predispositions are selectively
diagnosed. In the field of environmental and food analysis, it is possible with
the aid of nucleic acid analysis to detect minimal bacterial contamination or,
for instance, the use of genetically modified raw materials or food. To this
end, the individual steps which are today necessary to carry out a diagnosis are
all integrated in a single plastic cartridge thus miniaturizing a full-scale
laboratory to the area of a credit card. The analysis itself is carried out
fully automatically with the help of a control unit (analyzer). Net operating
time is reduced to a few minutes, the results are obtained right away. At the
end of last year, the R&D cooperation with Siemens Medical Solutions was
expanded into a full strategic partnership including the option for a future
participation. Market launch for the innovative diagnostic system is scheduled
already for 2005.
For more detailed information on the quarterly results and regarding the
development of our therapeutical involvements as well as our minority
participations, please visit our website www.november.de or contact:
Dr. Peer Nils Schröder
november AG – Investor Relations
Tel.: +49 (0)9131 750 88 868
email: schroeder@november.de
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hannover, München und Stuttgart
111037 Mai 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found